

AMERICAN GENE TECHNOLOGIES BUILDS MONTGOMERY COUNTY GENE & CELL THERAPY MOMENTUM

Fast Growing Maryland Biotech Company Moves to a 24,000 Sq. Ft. Location and Will Host Ribbon Cutting Ceremony on October 23, 2017

ROCKVILLE, MD, UNITED STATES, September 25, 2017 /EINPresswire.com/ -- [American Gene Technologies \(AGT\)](#), a private Maryland biotechnology company

developing cures and treatments for Infectious diseases, cancers and monogenic disorders, will celebrate the grand opening of its new 24,000 sq. ft. laboratory and offices. From its new location, AGT will begin clinical trials for its HIV Functional Cure therapeutic in the next six months.

The ribbon cutting ceremony highlights AGT's commitment to biotechnology in Maryland and will take place at its new location 9640 Medical Center Dr., Rockville, MD 20850 between 1-4pm on October 23rd.

The new AGT expansion will allow for acceleration of gene and cell therapeutic development laboratories supporting the HIV Functional Cure project that is expected to enter the clinic early next year, as well as to sustain the momentum of phenylketonuria and immuno-oncology therapeutics anticipated for clinical activities in late 2019. These early-stage programs represent substantial assets backed by an impressive IP portfolio. The new offices will support the company's expected growth through early 2020.

Specialized laboratories within the building will cover an impressive 11,500 sq. ft. of space. These include both a Vector Production Facility that allows the company to reliably produce research-grade lentivirus vector batches for cell and animal experiments, and a Translational Science Laboratory to enable broad validation of gene therapy drug candidates to further build AGT's extensive vector asset library.

The company's commitment to the local economy and job market is reflected in its plans to fill several positions over the coming months and into the first quarter of 2018. These include roles in clinical affairs, research and development, laboratory technicians, and others. In addition to providing space for new employees, AGT's new location has office clusters to inspire greater collaboration and interaction among groups, as well as extensive meeting space for vendor and/or collaborator interactions.

"We are delighted to be expanding our space here in Maryland, and are grateful to [Maryland Tech Council](#) for their support" said AGT's CEO Jeff Galvin. "Our new space will not only help to make product research, development, and testing more efficient and effective, but also enable us to further contribute to the growth of Maryland's biotechnology sector. This expansion continues our



commitment to provide job opportunities and growth within our local community.”

About AGT

AGT is developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, phenylketonuria (PKU), and hepatocellular carcinoma (liver cancer). Its drug candidates have achieved initial proof-of-concept in preclinical studies and have the potential to deliver cost-effective therapies that provide superior targeting and improved potency with fewer side effects. AGT's drugs will treat symptomatic disease but are intended to provide durable cures that extend the length and improve the quality of patients' lives.

<https://www.americangene.com/>

American Gene Technologies
9640 Medical Center Dr.
Rockville, MD 20850
info@americangene.com

For media inquiries, please contact: Sasha Whitaker, swhitaker@americangene.com.
For information on how to attend the event, please contact: Connie Ezerski,
cezerski@americangene.com

Sasha Whitaker
American Gene Technologies
(202) 997-2626
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2017 IPD Group, Inc. All Right Reserved.